Navigation Links
CardioMEMS Completes CHAMPION Clinical Trial Study
Date:6/1/2010

ATLANTA, June 1 /PRNewswire/ -- The CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients) trial met its primary efficacy endpoint with a 30% reduction in heart failure hospitalization rates at 6 months (p<0.001) in heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a tiny, permanent wireless implant.

The results were presented this week at the European Society of Cardiology Heart Failure Congress 2010 in Berlin, Germany, by the principal investigators of the trial:  William Abraham, M.D., Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center, and Philip Adamson, M.D., Director of the Heart Failure Institute at the Oklahoma Heart Hospital.  The study was sponsored by CardioMEMS, Inc., a medical technology company that has developed a novel wireless sensing and communication technology for the human body.

The CHAMPION trial evaluated the safety and effectiveness of the CardioMEMS heart failure (HF) pressure measurement system in New York Heart Association Class III (NYHA Class III) heart failure patients; these patients experience symptoms of heart failure with only mild exertion. NYHA Class III represents roughly 1.5 million of the six million heart failure patients in the U.S., and historically accounts for nearly half of all heart failure hospitalizations.

The CHAMPION Trial enrolled 550 patients, who had been hospitalized for heart failure in the previous year, at 63 leading heart centers in the U.S.  All subjects received the CardioMEMS CHAMPION HF sensor as a permanent pulmon
'/>"/>

SOURCE CardioMEMS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... $60.0 million aggregate principal amount of its convertible ... private placement to qualified institutional buyers pursuant to ... as amended (the "Act"). Egalet also granted the ...
(Date:4/1/2015)... April 1, 2015  Salix Pharmaceuticals, Ltd. ("Salix"), ... Inc. (NYSE: VRX ) (TSX:VRX), today announced ... $750,000,000 aggregate principal amount of its 6.00% Senior ... " Notes ") pursuant to two redemptions. On ... principal amount of the Notes, and on May ...
(Date:4/1/2015)... AVIV, Israel , April 1, 2015 /PRNewswire/ ... a clinical-stage biopharmaceutical company focused on the development ... the treatment of liver diseases and cholesterol gallstones, ... Tonelli as Vice President of Clinical Operations. ... progressive experience in clinical operations, development and regulatory ...
Breaking Medicine Technology:Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3
... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...
... vs. Drug-Eluting and Bare ... ... TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R stent has ... to Robbert de Winter, M.D., Ph.D.,principal investigator and director of the ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 Tempaper has ... a new virtual giving campaign that will raise critical ... people fighting muscle disease across the United States. , ... MDA through Tempaperdesigns.com will automatically receive free ... bring strength and urgently needed progress to children and ...
(Date:4/1/2015)... 01, 2015 eMindful , the ... of its executive team with the addition of veteran ... , In his new role, Suissa is ... interface across the business and consumer portals. He also ... the company’s online community. His hiring was a ...
(Date:4/1/2015)... 2015 Senior Helpers of Central Texas ... Provider of Choice Award by Home Care Pulse. The Best ... given to home care providers who receive the highest satisfaction ... quality in home care. This recognition reassures you that your ... provide you with quality, trustworthy in home care. , In ...
(Date:4/1/2015)... April 01, 2015 Skin cancer is one ... cured if caught early. Forefront Dermatology and Dermatology Associates of ... dangerous condition before it spreads so they are hosting a ... 11th from 8:30am - 12:30pm. , “If we can ... areas of concern, that could become cancerous,” said Dr. Ken ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Natural fertility ... Vancouver to attend the world’s first Integrative Fertility Symposium ... at Harbour Centre (SFU Downtown Campus), 515 West Hastings ... public talk Sunday, May 3rd, 3:00 pm to 5:00 ... is the first of its kind in the world ...
Breaking Medicine News(10 mins):Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 3Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3
... Fees on Transfer of Ordinary Shares Into ADRs to be Waived ... ... York, October 31 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; TASE: ... the Official List of the,United Kingdom Listing Authority, pursuant to the ...
... WESTMINSTER, Colo., Oct. 31 Allos,Therapeutics, Inc. (Nasdaq: ... commercialization of small molecule therapeutics for,the treatment of cancer, ... present a corporate overview at the 2007 Acumen BioFin ... presentation will take place at 8:50 a.m. (Eastern) on,Tuesday, ...
... Loss -, - New Drug Application Filing Planned by the End of ... ... -, SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Oct. ... LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today,announced positive ...
... ... Company, SANTA ... innovative medical devices used by interventional,radiologists and vascular surgeons for the ... disease, announced,today that it has named Dennis Rosenberg to the position ...
... 31 StemCor Systems, Inc., a,medical device ... today that it has received 510(k) clearance ... to market its MarrowMiner(TM),for the harvest of ... "Regulatory clearance of StemCor,s MarrowMiner is ...
... Alberta, Oct. 30 Medical Services,International Inc. (OTC Pink ... 4 additional distributors in the month of October, 2007. ... to purchase,a total of 750,000 test kits in the ... Fever and Malaria. There is a significant demand for,a ...
Cached Medicine News:Health News:XTL Announces Delisting From the Official List of the United Kingdom Listing Authority 2Health News:XTL Announces Delisting From the Official List of the United Kingdom Listing Authority 3Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 2Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 3Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 4Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 5Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 6Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 7Health News:Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study 8Health News:Bacchus Vascular Names Dennis Rosenberg as Vice President of Marketing 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 3
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
Medicine Products: